MAGED2 and gastric adenocarcinoma: A prognostic model was based on the hypoxia-associated transcription factors EHF, EIF1AD, GLA, KEAPI, and MAGED2, demonstrating remarkable efficacy in predicting the clinical outcomes of patients with STAD.